Guardant Health (GH) PT Raised to $67 at Guggenheim

Guggenheim analyst Subbu Nambi raised the price target on Guardant Health (NASDAQ: GH) to $67.00 (from $56.00) while maintaining a Buy rating.

The analyst commented: "Earlier today, GH hosted its 2025 Investor Day and provided updates on the business and its long range plan (LRP) through 2028. Key announcements include the upcoming launch of Shield MCD capabilities in October 2025, the 4Q25 launch of Reveal Response Monitoring, and the announcement of the Reveal Ultra tissue-informed MRD test in development. We are reiterating our BUY rating and raising our PT from $56 to $67."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• SpaceX files for 555.56M share IPO at $135/sh
• Bernstein SocGen Group Starts Cipher Mining (CIFR) at Outperform